AI summary by TwinMind

Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

Andrew Huberman

2h 52m 5s

Introduction and Definitions

  • Dr. Matthew Johnson directs Center for Psychedelic and Consciousness Research at Johns Hopkins
  • Psychedelic definition: compounds that profoundly alter sense of reality and self
  • Multiple pharmacological classes fall under "psychedelic" umbrella:
    • Classic psychedelics (LSD, psilocybin, DMT, mescaline) - serotonin 2A receptor agonists
    • NMDA antagonists (ketamine, PCP, dextromethorphan)
    • Kappa-opioid agonists (Salvinorin A from Salvia divinorum)
    • Entactogens (MDMA) - primarily serotonin release mechanism

Classic Psychedelics Mechanisms

  • Two structural classes: tryptamine-based (psilocybin, DMT) and phenethylamine-based (LSD, mescaline)
  • All act as serotonin 2A receptor agonists/partial agonists
  • Differ from serotonin itself - chemistry doesn't always predict receptor effects
  • Downstream effects include increased glutamate transmission
  • Profoundly alter predictive models brain uses to navigate reality

Clinical Trial Process at Hopkins

  • Extensive screening: psychiatric interviews, cardiovascular testing
  • Exclusions: psychotic disorders, bipolar disorder, family history of these conditions
  • 4-8 hours preparation with therapeutic guides
  • Session day: 20-30mg psilocybin (pure compound, not mushrooms)
  • No body weight adjustment needed (brain size doesn't vary significantly)
  • Eye shades worn, supportive environment with guides present
  • Cardiovascular monitoring throughout (blood pressure, pulse every 30 minutes)
  • Integration session next day after writing about experience

Therapeutic Approach and Mechanisms

  • "Letting go" central to therapeutic process - surrendering control vs. trying to maintain it
  • Bad trips occur in ~1/3 of high-dose sessions even with preparation
  • Gateway between challenging experience and transcendental mystical experience
  • Changes in self-representation appear to be key therapeutic mechanism
  • Persistent effects lasting months to over a year
  • "Duh experiences" - profound sense of agency and ability to change

MDMA Differences

  • Synthetic compound, increases both serotonin and dopamine release
  • Less likely to cause challenging experiences compared to classic psychedelics
  • Particularly effective for PTSD - reduces amygdala reactivity
  • Allows reprocessing of traumatic memories without fight-or-flight response
  • Currently approved as Spravato (esketamine) but not treated as psychedelic therapy

Safety Considerations and Risks

  • Two main dangers: psychiatric predisposition and bad trips in unsafe environments
  • Rare cases of prolonged psychiatric issues in vulnerable individuals
  • HPPD (hallucinogen-persisting perceptual disorder) very rare, never seen in clinical trials
  • May be related to rare neurological susceptibility, not specific to psychedelics
  • Flashbacks often state-dependent learning or brief perceptual anomalies

Microdosing

  • ~1/10th of psychedelic dose (1mg psilocybin, 10-20 micrograms LSD)
  • Claims: better focus (Adderall alternative), antidepressant effects
  • No peer-reviewed studies show cognitive enhancement or sustained mood improvement
  • Some studies show slight impairment in time estimation
  • Potential concern: chronic 5-HT2B receptor activation could cause heart valve problems
  • More research needed on specific dosing protocols advocated by enthusiasts

Age and Development

  • FDA pushing for pediatric studies despite no current research
  • Concerns about developing brain susceptibility vs. increased plasticity
  • Treatment-resistant cases in adolescents may be first targets
  • Age 25 inflection point for neural plasticity, but individual variation exists

Legal Status and Future

  • Currently Schedule I federally, but state/local decriminalization varies
  • Oregon state-level legalization of psilocybin therapy in development
  • MDMA likely FDA-approved for PTSD within 3 years in clinical settings
  • Psilocybin breakthrough therapy designation for depression
  • Medical development separate from decriminalization efforts
  • Future regulation model may require training/licensing rather than criminalization

Traumatic Brain Injury Research

  • Exploratory work with UFC fighters and retired athletes
  • Anecdotal reports of cognitive improvement after psychedelic use
  • Animal studies show neural plasticity: dendritic growth, new connections
  • Targeting depression in TBI patients with secondary aim of cognitive improvement
  • MRI studies to assess gray matter changes over time

Funding and Academic Support

  • Primarily philanthropic funding: Heffter Research Institute, Beckley Institute, Council on Spiritual Practices
  • $17 million gift from Cohen Foundation and Tim Ferriss collaborative created center
  • Limited NIH/NIDA funding only for abuse liability studies
  • Breakthrough therapy designations worth millions in pharmaceutical development
  • Academic freedom to focus on therapeutic applications rather than abuse potential

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome